Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Survodutide (BI 456906) in Hepatic Impairment and Obesity
NCT05296733Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Peptides
- Countries
- 6
01
Overview
Phase 1, open-label trial of survodutide in obesity (7 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to infinity up to 360 hours, Maximum measured concentration up to 360 hours and 1 more. Started Apr 2022; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05296733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296733.